Indication-specific pricing of pharmaceuticals in the US healthcare system

To explore the potential of indication-specific pricing (ISP) of pharmaceuticals and to discuss prospects for implementation in the US healthcare system. The Institute for Clinical and Economic Review convened a policy forum with 44 healthcare leaders from 22 payer and life sciences companies. Model...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of comparative effectiveness research 2017-07, Vol.6 (5), p.397-404
Hauptverfasser:	Pearson, Steven D, Dreitlein, William B, Henshall, Chris, Towse, Adrian
Format:	Artikel
Sprache:	eng
Schlagworte:	Costs and Cost Analysis Delivery of Health Care - economics Drug Costs Drug Industry - economics Drug Industry - legislation & jurisprudence Drugs, Generic - economics health policy Humans indication-specific pricing Institute for Clinical and Economic Review Legislation, Drug Medicaid - economics Medicare - economics multi-indication drugs Off-Label Use - economics payers pharmaceutical manufacturers Pharmaceutical Preparations - economics Pharmacopoeias as Topic reimbursement Reimbursement Mechanisms - economics Reimbursement Mechanisms - legislation & jurisprudence United States value-based pricing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!